COMMUNICATION:
Proteasome- and p53-dependent Masking of Signal Transducer and Activator of Transcription (STAT) Factors*

(Received for publication, December 4, 1996)

Ravi J. Rayanade Dagger , Kirit Patel Dagger , Mackevin Ndubuisi Dagger , Sansar Sharma Dagger §, Satoshi Omura , Joseph D. Etlinger Dagger , Richard Pine par and Pravin B. Sehgal Dagger **Dagger Dagger

From the Departments of Dagger  Cell Biology & Anatomy, § Ophthalmology, and ** Medicine, New York Medical College, Valhalla, New York 10595,  The Kitasato Institute, 9-1 Shirokane 5-Chome, Minato-ku, Tokyo 108, Japan, and the par  Public Health Research Institute, New York, New York 10016

ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
FOOTNOTES
Acknowledgments
REFERENCES


ABSTRACT

Hepatoma Hep3B cell lines stably expressing a temperature-sensitive p53 species (p53-Val-135) displayed a reduced response to interleukin-6 (IL-6) when cultured at the wild-type (wt) p53 temperature (Wang, L., Rayanade, R., Garcia, D., Patel, K., Pan, H., and Sehgal, P. B. (1995) J. Biol. Chem. 270, 23159-23165). We now report that in such cultures IL-6 caused a rapid (20-30 min) and marked loss of cellular immunostaining for STAT3 and STAT5, but not for STAT1. The loss of STAT3 and STAT5 immunostaining was transient (lasted 120 min) and tyrosine kinase-dependent, and even though the loss was blocked by the proteasome inhibitors MG132 and lactacystin it was not accompanied by changes in cellular levels of STAT3 and STAT5 proteins suggesting that IL-6 triggered a rapid masking but not degradation of these transcription factors. STAT3 and STAT5 masking was accompanied by a reduction in IL-6-induced nuclear DNA-binding activity. The data suggest that p53 may influence Jak-STAT signaling through a novel indirect mechanism involving a wt p53-dependent gene product which upon cytokine addition is activated into a "STAT-masking factor" in a proteasome-dependent step.


INTRODUCTION

The cellular protein p53 has been implicated in the regulation of mammalian cell processes such as proliferation, apoptosis, and DNA repair either directly as a transcription factor which modulates expression of specific regulatory genes or indirectly as a transcription factor which up-regulates the expression of genes whose products, in turn, then regulate other cellular regulatory proteins (1-8). As an example of the latter, the inhibitory effect of p53 on the cell cycle is attributed to the ability of p53 to increase the transcriptional expression of p21, a cellular protein which inhibits cyclin kinases, thus inhibiting the function of cyclins, a class of regulatory proteins required for cell proliferation (5-8). Despite clear evidence of the influence of cytokines upon p53-induced cellular processes, for example the rescue of p53-induced apoptosis in myeloid cells by the cytokine interleukin-6 (IL-6)1 (9-14), there is little information concerning the influence, direct or indirect, of p53 upon cytokine-elicited cellular signaling through the Janus kinase-<UNL>s</UNL>ignal <UNL>t</UNL>ransducers and <UNL>a</UNL>ctivators of <UNL>t</UNL>ranscription (Jak-STAT) pathway.

We previously utilized a constitutive expression vector for the temperature-sensitive p53 mutant (p53-Val-135) (2, 9) to obtain a series of stably transfected human hepatoma Hep3B cell lines that displayed a reduced response to IL-6 at the wild-type (wt) p53 temperature (32.5 °C) (14). The temperature dependence of the secretion of plasma proteins such as beta -fibrinogen and alpha 1-antichymotrypsin in response to IL-6 by these p53-Val-135-expressing Hep3B lines, but not by the pSVneo control cell lines or the p53-free parental Hep3B cells, suggested that wt p53 negatively influenced cytokine signaling (14). In as much as the transcriptional response to IL-6 of the beta -fibrinogen and alpha 1-antichymotrypsin genes is primarily through activation of STAT3 and STAT5 transcription factors through the Jak-STAT signaling pathway (15-18), our previous data suggested that p53 might, directly or indirectly, influence Jak-STAT signaling in these p53-Val-135-expressing Hep3B cell lines at 32.5 °C (the wt p53 temperature).

In the present study, we used confocal immunofluorescence microscopy to investigate the fate of transcription factors involved in Jak-STAT signaling upon addition of IL-6 to cultures of mutant or wt p53-containing Hep3B cells. It has been shown previously that the multicatalytic 26 S proteasome is involved in degradation or processing of many cellular proteins which include the transcription factors NF-kappa B1 (p50), I-kappa Balpha , c-Jun, and c-Fos (19-28). The use of proteasome inhibitors such as MG132 (19-24) and lactacystin (25-28) has greatly assisted in delineating the role of proteasomes in the turnover/processing of cellular transcription factors. For example, the cytokine-induced phosphorylation-dependent degradation of I-kappa Balpha through the ubiquitin-proteasome pathway is now well characterized (21-23). The data obtained in the present study suggest that p53 may influence Jak-STAT signaling through a novel indirect mechanism involving a wt p53-dependent gene product which upon IL-6 addition is rapidly activated into a STAT3 and STAT5 "masking" factor in a proteasome-dependent step.


MATERIALS AND METHODS

p53-Val-135-expressing Hepatoma Hep3B Cell Lines

A series of 11 stably transfected cell lines constitutively expressing p53-Val-135 and seven control cell lines expressing pSVneo alone were derived from the p53-free human hepatoma Hep3B line as has been described earlier (14). Line 1 and Line 5 cells which express p53-Val-135 were used in the data shown in this communication.

Immunofluorescence Analyses for STAT Transcription Factors

For immunofluorescence assays, cells were planted in wells of 8-chamber slides (Nunc; 2 × 104cells/chamber) in 0.3 ml of Dulbecco's modified Eagle's high glucose medium supplemented with 1 mM L-glutamine, 2 mM sodium pyruvate, 1 × non-essential amino acids, and 10% (v/v) fetal bovine serum (all obtained from Life Technologies, Inc.). The cultures were incubated at 37 °C for 18-24 h and then either continued at 37 °C or shifted to 32.5 °C for 18-24 h. All cultures were then washed twice with phosphate-buffered saline (PBS) previously equilibrated to the respective temperatures and replenished with 0.3 ml of serum-free medium also previously equilibrated at the respective temperatures. Four hours after the switch to serum-free medium, the cells were treated with human IL-6 (Escherichia coli-derived, a gift from Sandoz) (30 ng/ml) for 30 min. At the end of the IL-6 treatment, the cultures were washed with ice-cold PBS, drained, and fixed with cold methanol/acetone (2:1) for 10 min, the fixative was drained, and the slides were allowed to air dry. Immunostaining using various monoclonal and polyclonal antibodies was carried out as per the instructions provided by the respective antibody suppliers using fluorescein-tagged goat anti-murine IgG or rhodamine-tagged goat anti-rabbit IgG (Cappel Organon Teknika). Cellular immunofluorescence was evaluated using a Bio-Rad MRC 1000 dual laser confocal microscopy system. Murine monoclonal antibodies to STAT1, STAT3, and STAT5a (marketed as anti-"STAT5") were purchased from Transduction Laboratories, murine monoclonal antibody to STAT5b and rabbit polyclonal antibody to STAT3 were purchased from Santa Cruz Biotech, and anti-p53 monoclonal antibodies PAb240 and PAb421 were purchased from Oncogene Research Products/Calbiochem.

Western Blot Analyses for STAT Proteins

The whole cell lysis buffer used and Western blot procedure were as per protocol provided by Transduction Laboratories using the ABC Elite Vectastain kit (Vector Laboratories). Aliquots containing equal total cellular protein amounts in the range of 30-40 µg (Bio-Rad Micro Assay, Bio-Rad) were loaded in each lane of particular Western blots.

DNA Gel-shift Assays

Nuclear extracts were prepared essentially as described earlier (29), and STAT-specific DNA-binding activity was assayed using a "GAS" (gamma -interferon activated site) double-stranded DNA element from the interferon response factor-1 promoter (top strand 5'-gatcGATTTCCCCGAAATcgagatc-3'; lower case letters are linkers) which yields the typical pattern of A, B, and C complexes in gel-shift assays corresponding to STAT3 homodimer, STAT1/3 heterodimer, and STAT1 homodimer, respectively (29, 30).


RESULTS AND DISCUSSION

The confocal immunofluorescence data in Fig. 1A confirm the temperature-sensitive (ts) phenotype of the conformation of p53-Val-135 expressed in Line 5: mutant conformation at 37 °C and wt conformation at 32.5 °C. All 11 p53-Val-135-expressing Hep3B cell lines showed this ts phenotype with respect to p53 conformation. None of the seven pSVneo control lines nor the parental Hep3B cells showed immunostaining for p53. When cultures of Line 5 cells were first incubated at 37 °C for 1 day, shifted to 32.5 °C for 18-20 h, and then exposed to IL-6 for 30 min, there was a marked loss of STAT3 and STAT5 immunostaining but not that of STAT1 (Fig. 1B). Cultures kept throughout at 37 °C did not display the loss of STAT3 and STAT5 immunostaining (Fig. 1B). All 11 of the p53-Val-135-expressing Hep3B cell lines displayed a loss of STAT3 and STAT5 immunostaining 30 min after IL-6 addition at 32.5 °C, whereas none of the 7 pSVneo control lines nor the parental Hep3B cells displayed any loss of STAT3 or STAT5 immunostaining upon IL-6 addition at either 32.5 or 37 °C (data not shown).


Fig. 1. Temperature dependence of p53-Val-135 conformation (Panel A) and of loss of STAT3 and STAT5 immunostaining at 32.5 °C (Panel B) in IL-6-treated Line 5 Hep3B cells. This figure illustrates confocal immunofluorescence microscopy of cells first cultured at 37 °C for 1 day and then shifted to 32.5 °C for 18-20 h followed by treatment with IL-6 (30 ng/ml) for 30 min. The white bar in this and in Figs. 2 and 3 corresponds to 20 µM; all data within each experiment were collected at identical black level and gain settings. Panel A, immunostaining for p53 using either the mutant p53 conformation-specific murine monoclonal antibody (mAb) PAb240 or the panreactive antibody PAb421. Panel B, loss of STAT3 and STAT5 immunostaining at 32.5 °C but not at 37 °C in IL-6-treated cultures. Line 5 cells at the two temperatures were treated with IL-6 (30 ng/ml) for 30 min prior to fixation. Murine mAb to STAT1, STAT3, and STAT5 (which cross-reacts with native STAT5b) were used in the immunostaining analyses illustrated.
[View Larger Version of this Image (40K GIF file)]


The loss of STAT3 and STAT5 immunostaining as illustrated in Fig. 1B (i) was IL-6-induced and rapid in that a reduction in immunostaining was observed within 10 min and there was almost complete loss by 20-30 min after IL-6 addition, (ii) was transient in that STAT3 and STAT5 immunostaining returned 120-240 min after IL-6 addition, (iii) was dependent upon cytokine concentration in that, when assayed 30 min after IL-6 addition, the loss of immunostaining was elicited by IL-6 at 0.3 ng/ml, was near-maximal at 3-10 ng/ml, and was still evident at 100 ng/ml, (iv) was selective in that a loss of immunostaining was not observed for STAT1, STAT4, STAT6, RelA (p65), C/EBPalpha , beta , gamma , and Sp1 transcription factors, (v) was cytokine-specific in that interferon-gamma elicited a modest reduction in STAT3 immunostaining but no loss of STAT5 or STAT1 immunostaining, and epidermal growth factor elicited no changes in immunostaining of any STAT transcription factors, (vi) required that the p53-Val-135-expressing Hep3B cells be incubated for at least 18-20 h at the wt p53 temperature (32.5 °C) in that a 5- or 10-h incubation at 32.5 °C was insufficient to elicit this phenotype, and (vii) was not dependent upon rapid de novo protein synthesis upon IL-6 addition in that the protein synthesis inhibitor cycloheximide added 30 min prior to IL-6 did not inhibit the cytokine-induced loss of STAT3 or STAT5 immunostaining (data not shown).

The loss of IL-6-triggered STAT3 immunostaining was observed using an anti-STAT3 monoclonal antibody or an anti-STAT3 polyclonal antibody each raised to different peptides from different regions of the STAT3 amino acid sequence (data not shown). Similarly, the loss of IL-6-triggered STAT5 immunostaining was observed using an anti-STAT5a monoclonal antibody (which cross-reacts with STAT5b in its native form) as well as using an anti-STAT5b monoclonal antibody (data not shown). In these Hep3B cell lines, significant nuclear immunostaining for STAT1 and STAT5, as in Fig. 1B, was observed even in the absence of IL-6 addition. IL-6 addition did not result in any clear cytoplasm to nuclear translocation of STAT1 or STAT5 immunostaining. In the case of STAT3, although cytoplasmic immunostaining predominated, some nuclear staining was always seen even in the absence of IL-6 addition. There was increased STAT3 nuclear staining upon IL-6 addition at 37 °C (as in Fig. 1B).

The dramatic loss of STAT3 and STAT5 immunostaining upon IL-6 addition to Line 5 cells at 32.5 °C was dependent upon tyrosine kinase activity in that it was blocked by the tyrosine kinase inhibitor genistein and by staurosporine but not by the protein kinase C inhibitor H7 (Fig. 2) (15-18). Tyrosine phosphorylation of STAT3 and STAT5 upon IL-6 addition is known to occur within 1-5 min and to reach a maximum by 20-30 min (15-18) consistent with the time course of disappearance of STAT3 and STAT5 immunostaining (Fig. 1 and data not shown).


Fig. 2. Loss of STAT3 immunostaining is IL-6-induced and requires Tyr(P) kinase. Line 5 cultures were evaluated for the effect of genistein (100 µM), staurosporine (10 µM), and H7 (10 µM and 100 µM) (Sigma) upon the IL-6-induced loss of STAT3 and STAT5 immunostaining in cultures shifted down to 32.5 °C for 20 h. The various inhibitors were added 30 min prior to IL-6 treatment (30 ng/ml for 30 min). This figure illustrates data obtained using anti-STAT3 mAb for immunostaining; similar results were obtained using anti-STAT5 mAb for immunostaining (data not shown). DMSO, dimethyl sulfoxide.
[View Larger Version of this Image (101K GIF file)]


The cytokine-triggered loss of STAT3 and STAT5 transcription factors suggested the involvement of proteasomes in this phenomenon. Fig. 3 shows that the proteasome inhibitors MG132 and lactacystin both blocked the IL-6-induced loss of STAT3 and STAT5 immunostaining providing evidence for a proteasome-dependent step in this mechanism.


Fig. 3. Proteasome dependence of IL-6-induced loss of STAT3 immunostaining. Line 5 cultures 20 h following shift-down to 32.5 °C as described in Fig. 1B were treated with lactacystin (25 µM) or MG132 (40 µM) (Myogenics) for 30 min prior to the addition of IL-6 (30 ng/ml) for 30 min. Following fixation, immunostaining for STAT3 and STAT5 was evaluated using the respective anti-STAT mAb. This figure illustrates the anti-STAT3 immunostaining data; similar results were obtained using anti-STAT5 mAb (data not shown).
[View Larger Version of this Image (102K GIF file)]


The possibility that the loss of STAT3 and STAT5 immunostaining was the result of a degradation of the respective STAT proteins was evaluated by Western blot analyses. The total cellular amounts of STAT3 and STAT5b (Hep3B cells contain STAT5b but little STAT5a; Refs. 15-18 and 30)2 showed no change upon addition of IL-6 (Fig. 4A) or upon addition of IL-6 in combination with MG132 or lactacystin (Fig. 4B). Thus the marked loss of STAT3 and STAT5 immunostaining was not accompanied by a loss of STAT3 and STAT5 Western blottable proteins suggesting that the loss of immunostaining was an IL-6-triggered masking of STAT3 and STAT5 proteins and not the result of the degradation of these transcription factors. The observation that p53-Val-135-containing cultures had to be incubated at the wt p53 temperature (32.5 °C) for at least 18-20 h before the IL-6-induced loss of STAT3 and STAT5 immunostaining could be elicited suggested that a wt p53-induced gene product which accumulated in these cells in the 18-20-h period was activated in a proteasome- and tyrosine phosphorylation-dependent step upon IL-6 addition into a novel STAT-masking factor. The simplest possibility is that upon IL-6 addition a wt p53-induced protein is proteasomally processed into the STAT-masking factor which binds tyrosine-phosphorylated STAT3 and STAT5.


Fig. 4. Western blot analyses of STAT3 and STAT5 content in IL-6-treated Line 5 cells exhibiting the IL-6-induced loss of STAT3 and STAT5 immunostaining. Experimental conditions were similar to those in Figs. 2 and 3 except that cultures of Line 5 cells were prepared in 100-mm Petri dishes (Nunc). Panel A, STAT3 and STAT5b content of Line 5 cells at different times after IL-6 addition (30 ng/ml) at 32.5 °C (experimental conditions similar to those in Fig. 2). Panel B, STAT1alpha , STAT3, and STAT5b content of Line 5 cells 30 min after IL-6 addition together with various proteasome inhibitors (experimental conditions similar to those in Fig. 3).
[View Larger Version of this Image (43K GIF file)]


The functional consequences of STAT-factor masking and the effect of proteasomal inhibitors upon nuclear STAT-DNA-binding activity were evaluated in experiments in which nuclear extracts prepared from IL-6-treated p53-Val-135-expressing cells incubated at either 37 °C or 32.5 °C were evaluated for their ability to bind a canonical STAT-binding DNA element. Fig. 5 shows that, consistent with the masking phenomenon illustrated in Fig. 1, IL-6 had a reduced ability to elicit STAT3 homodimer DNA-binding activity ("Complex A") in nuclear extracts prepared from cells at 32.5 °C compared to cells at 37 °C. Similar data were obtained in experiments with both Line 1 and Line 5 cell lines. As a control, there was no difference in the levels of interferon-gamma activated STAT1 DNA-binding activity detected in the nuclear extracts of Line 1 or Line 5 cells cultured at either 37 °C or 32.5 °C (data not shown), consistent with the observation that immunostaining for STAT1 was not "masked" upon interferon-gamma treatment of Line 5 (or Line 1) cells at 32.5 °C.


Fig. 5. STAT-specific DNA-binding activity in nuclear extracts of p53-Val-135-expressing Hep3B cells first cultured (in 100-mm Petri dishes) at 37 °C for 1 day, shifted to the indicated temperature for 20 h, and then exposed to IL-6 or MG132 or both. Cell cultures were exposed to MG132 (40 µM) for 30 min prior to the addition of IL-6 (30 ng/ml) and then for another 30 min in the continued presence of both IL-6 and MG132. ns, non-specific DNA binding.
[View Larger Version of this Image (60K GIF file)]


Fig. 5 also shows that, at both temperatures, the inclusion of MG132 increased STAT-DNA binding corresponding to Complex C (STAT1 homodimer), Complex B (STAT1/3 heterodimer), Complex A (STAT3 homodimer), as well as a slower mobility complex (Complex A*, presumably corresponding to STAT5), an observation consistent with the effect of MG132 on STAT-specific cellular immunofluorescence (Fig. 3). The increase in STAT1 DNA-binding complexes ("Complex C") in IL-6-treated cells which had also been exposed to MG132 extends a recent report implicating proteasomes in the turnover/degradation of ubiquitinated and tyrosine-phosphorylated STAT1 protein in interferon-gamma -treated cells (31).

Prior data from many laboratories have clearly established the ability of cytokines such as IL-6 to influence p53-dependent cellular events and vice versa (9-14). The underlying mechansims have remained elusive. The cytokine-triggered proteasome- and p53-dependent masking of STAT-family transcription factors described in this report represents a novel indirect mechanism for the regulation of cytokine responses by a wt p53-induced gene product. The eventual identification and characterization of the p53-induced STAT-masking factor and the elucidation of its physiological function is likely to add a new, proteasomal, dimension to our understanding of the regulation of cytokine-activated Jak-STAT signaling.


FOOTNOTES

*   This work was supported by Research Grant IM-701B from the American Cancer Society and a contract from the National Foundation for Cancer Research. The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Dagger Dagger    To whom correspondence should be addressed: Dept. of Cell Biology & Anatomy, Basic Science Bldg., New York Medical College, Valhalla, NY 10595. Tel.: 914-993-4196; Fax: 914-993-4825.
1    The abbreviations used are: IL-6, interleukin-6; Jak, Janus kinase; mAb, monoclonal antibody; PBS, phosphate-buffered saline; STAT, signal transducer and activator of transcription; ts, temperature-sensitive; wt, wild type.
2    R. J. Rayanade and P. B. Sehgal, unpublished data.

Acknowledgments

We thank Victor Fried for helpful discussions and a critical review of the data and Pramila Warke, Manohar V. N. Shirodkar, Elyse S. Goldweber, Josephine Lauriello, Suzanne Andrews, and Kimberly A. Sorrentino for their encouragement and support.


REFERENCES

  1. Michalovitz, D., Halevy, O., and Oren, M. (1990) Cell 62, 671-680 [Medline] [Order article via Infotrieve]
  2. Fields, S., and Jang, S. J. (1990) Science 249, 1046-1049 [Medline] [Order article via Infotrieve]
  3. Levine, A. J., Momand, J., and Finlay, C. A. (1991) Nature 351, 453-456 [CrossRef][Medline] [Order article via Infotrieve]
  4. Oliner, J. D. (1993) BioEssays 15, 703-707 [Medline] [Order article via Infotrieve]
  5. El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., and Vogelstein, B. (1993) Cell 75, 817-825 [Medline] [Order article via Infotrieve]
  6. Harper, J. W., Adami, G. R., Wei, N., Keyomarsi, K., and Elledge, S. J. (1993) Cell 75, 805-816 [Medline] [Order article via Infotrieve]
  7. Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R., and Beach, D. (1993) Nature 366, 701-704 [CrossRef][Medline] [Order article via Infotrieve]
  8. Serrano, M., Hannon, G. J., and Beach, D. (1993) Nature 366, 704-707 [CrossRef][Medline] [Order article via Infotrieve]
  9. Yonish-Rouach, E., Resnitzky, D., Lotem, J., Sachs, L., Kimchi, A., and Oren, M. (1991) Nature 352, 345-347 [CrossRef][Medline] [Order article via Infotrieve]
  10. Santhanam, U., Ray, A., and Sehgal, P. B. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 7605-7609 [Abstract]
  11. Levy, N., Yonish-Rouach, E., Oren, M., and Kimchi, A. (1993) Mol. Cell. Biol. 13, 7942-7952 [Abstract]
  12. Margulies, L., and Sehgal, P. B. (1993) J. Biol. Chem. 268, 15096-15100 [Abstract/Free Full Text]
  13. Gottlieb, E., Haffner, R., von Ruden, T., Wagner, E., and Oren, M. (1994) EMBO J. 13, 1368-1374 [Abstract]
  14. Wang, L., Rayanade, R., Garcia, D., Patel, K., Pan, H., and Sehgal, P. B. (1995) J. Biol. Chem. 270, 23159-23165 [Abstract/Free Full Text]
  15. Darnell, J. E., Jr., Kerr, I. M., and Stark, G. R. (1994) Science 264, 1415-1421 [Medline] [Order article via Infotrieve]
  16. Schindler, C., and Darnell, J. E., Jr. (1995) Annu. Rev. Biochem. 64, 621-651 [CrossRef][Medline] [Order article via Infotrieve]
  17. Lai, C.-F., Morella, K. K., Wang, Y., Kumaki, S., Gearing, D., Zeigler, S. F., Tweardy, D. J., Campos, S. P., and Baumann, H. (1995) Ann. N. Y. Acad. Sci. 762, 189-205 [Medline] [Order article via Infotrieve]
  18. Ihle, J. N. (1996) Cell 84, 331-334 [Medline] [Order article via Infotrieve]
  19. Palombella, V. J., Rando, O. J., Goldberg, A. L., and Maniatis, T. (1994) Cell 78, 773-785 [Medline] [Order article via Infotrieve]
  20. Rock, K. L., Gramm, C., Rothstein, L., Clark, K., Stein, R., Dick, L., Hwang, D., and Goldberg, A. L. (1994) Cell 78, 761-771 [Medline] [Order article via Infotrieve]
  21. Scherrer, D. C., Brockman, J. A., Chen, Z., Maniatis, T., and Ballard, D. W. (1995) Proc. Natl. Acad. Sci U. S. A. 92, 11259-11263 [Abstract]
  22. Chen, Z., Hagler, J., Palombella, V. J., Melandri, F., Scherer, D., Ballard, D., and Maniatis, T. (1995) Genes Dev. 9, 1586-1597 [Abstract]
  23. Jensen, T. J., Loo, M. A., Pind, S., Williams, D. B., Goldberg, A. L., and Riordan, J. R. (1995) Cell 83, 129-135 [Medline] [Order article via Infotrieve]
  24. Roff, M., Thompson, J., Rodriquez, M. S., Jacque, J.-M., Baleux, F., Arenzana-Seisdedos, F., and Hay, R. T. (1996) J. Biol. Chem. 271, 7844-7850 [Abstract/Free Full Text]
  25. Omura, S., Fujimoto, T., Otoguro, K., Matsuzaki, K., Moriguchi, R., Tanaka, H., and Sasaki, Y. (1991) J. Antibiot. (Tokyo) 44, 113-116 [Medline] [Order article via Infotrieve]
  26. Fenteany, G., Standaert, R. F., Reichard, G. A., Corey, E. J., and Schreiber, S. L. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 3358-3362 [Abstract]
  27. Fenteany, G., Standaert, R. F., Lane, W. S., Choi, S., Corey, E. J., and Schreiber, S. L. (1995) Science 268, 726-731 [Medline] [Order article via Infotrieve]
  28. Dick, L. R., Cruickshank, A. A., Gernier, L., Melandri, F. D., Nunes, S. L., and Stein, R. L. (1996) J. Biol. Chem. 271, 7273-7276 [Abstract/Free Full Text]
  29. Horvath, C. M., Wen, Z., and Darnell, J. E., Jr. (1995) Genes Dev. 9, 984-994 [Abstract]
  30. Lin, J.-X., Mietz, J., Modi, W. S., John, S., and Leonard, W. J. (1996) J. Biol. Chem. 271, 10738-10744 [Abstract/Free Full Text]
  31. Kim, T. K., and Maniatis, T. (1996) Science 273, 1717-1719 [Abstract/Free Full Text]

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.